Abstract: The present invention relates to the technical field of mine fire prevention and extinguishing, in particular to a liquid nitrogen direct injection and low-temperature foaming intelligent filling system based on mine fire area characteristics and an application method, comprising a liquid nitrogen storage tank, a liquid nitrogen direct injection system and a low-temperature foaming system, wherein the liquid nitrogen storage tank communicates with a liquid nitrogen pressurizing device through a main pipeline; a temperature control unit is arranged on the main pipeline; and the liquid nitrogen pressurizing device is connected with the liquid nitrogen direct injection system and the low-temperature foaming system, respectively, liquid nitrogen is directly injected into a foam liquid, to prepare a low-temperature foam type fire preventing and extinguishing material by means of forced convection, membrane boiling, explosion boiling and nucleate boiling between the liquid nitrogen and water.

Abstract: Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.

Abstract: Disclosed is a molecule, e.g., a single-domain antibody, or a heavy chain only antibody, that specifically binds human PD-LI, and its use in treating diseases such as tumors.

Abstract: Disclosed is a single chain fragment variable (scFv), comprising a heavy chain variable region, a linker and a ? light chain variable region, wherein the ? light chain variable region is engineered to comprise leucin (L), threonine (T) and alanine (A) at Position 104 to 106 according to the Kabat numbering scheme.

Abstract: Disclosed is a bispecific molecule specifically binding TIGIT and VEGF, and its use in treatment of e.g., tumors.

Abstract: Disclosed is a monoclonal antibody that specifically binds BCMA, or an antigen binding fragment thereof, and its use in treating cancers such as multiple myeloma. Also disclosed is a monoclonal antibody that specifically binds CD3, or an antigen binding fragment thereof, and its use in treating or alleviating an inflammatory disease, an autoimmune disease, or transplantation rejection. Further disclosed is an anti-BCMA/CD3 bispecific antibody, and its use in treating diseases such as cancers.

Abstract: A method of re-routing an off route vehicle is described. A transportation system provides a route from an origin to a destination to a client device associated with a driver of the route. The transportation system receives location data from the client device associated with the driver and calculates one or more error values based on the location data. The transportation system provides a re-route to the client device based on determining that the one or more error values are greater than a threshold value.

Abstract: The invention relates to a tube (100) with a hollow cylindrical elastic base structure (102) for insertion into a blood vessel (200) of a vascular system (202). The tube (100) comprises an outer anisotropic surface structure (104) comprising a geometrical anisotropy between a direction circumferential to the tube and a direction longitudinal to the tube (100). The anisotropic surface structure (104) is configured for establishing an anisotropic friction between the anisotropic surface structure (104) and an inner surface of the blood vessel (200). The anisotropic friction results in a surface propulsion of the tube (100), when the tube (100) is rotated around a central longitudinal body axis (106) of the tube (100). The tube (100) further comprises a magnetic material (108) distributed circumferentially around the tube (100) and configured for establishing within an external magnetic field a rotation of the tube (100) around the central longitudinal body axis (106) of the tube (100).

Abstract: The present invention relates to a method of fabricating magnetic deformable machines comprising heterogeneous voxels, as well as to a deformable 3D magnetic machine, the magnetic machine having a size of less than 10000 mm, the magnetic machine comprising a plurality of voxels of which at least some are magnetic, with at least some of the voxels having a Young's modulus of less than 500 MPa, the plurality of voxels being bonded one to another with a bonding agent, wherein each voxel is of predefined shape, size, has predefined magnetic properties and predefined material properties.

Abstract: A microfluidic chip device based on a magnetic field-controlled fluorescently labeled cell sorting method and a use method are disclosed. The microfluidic chip comprises a sample channel, two sheath fluid channels, a first fluorescence detection area, a second fluorescence detection area, a magnetic field control system, a magnetic field-controlled cell sorting area, a target cell channel, and a waste fluid channel. Based on fluorescence signals labeled on the cells, the FACS system is combined with a magnetic field-controlled sorting system to achieve automated cell sorting, which not only miniaturizes and automates the sorting detection integration, but also has the advantages of easy and economical operation. The device sorts both a large number of cell samples and a small number of cell samples, thus overcoming the defects of a flow cytometer.

Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD0-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human TIGIT. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.

Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.

Abstract: A coordination server receives a request from a client device of a rider for transportation from a first location. The coordination server identifies a frequent spot based on the first location. The frequent spot is associated with a particular location and represents a plurality of historic first locations within a threshold distance from the frequent spot. The coordination server identifies a closest road segment with respect to the frequent spot. The closest road segment is a road segment of a plurality of road segments of an electronic map representing a geographic area around the first location. The coordination server determines a pickup side of the closest road segment based on the first location and the closest road segment. The coordination server sends, to a client device of a driver, a route to the first location such that the driver arrives on the pickup side of the closest road segment.

Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.

Abstract: The present invention relates to a method of actuating a shape changeable member of actuatable material. The invention further relates to a shape changeable member and to a system comprising such a shape changeable member and a magnetic field apparatus.

Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human LAG3. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof thereof, as well as a treatment method using the same.

Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.

Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.

Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.